Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Accured Expenses (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Change in Accured Expenses data on record, last reported at -$56.3 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 1.0% year-over-year to -$56.3 million; the TTM value through Dec 2025 reached -$2.4 million, down 159.1%, while the annual FY2025 figure was -$2.4 million, 159.1% down from the prior year.
  • Change in Accured Expenses reached -$56.3 million in Q4 2025 per TGTX's latest filing, down from -$17.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $65.6 million in Q1 2025 and bottomed at -$56.8 million in Q4 2024.
  • Average Change in Accured Expenses over 5 years is $341050.0, with a median of $1.0 million recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 2486.77% in 2022, down 5723.55% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $17.5 million in 2021, then dropped by 6.13% to $16.4 million in 2022, then crashed by 84.39% to $2.6 million in 2023, then plummeted by 2316.11% to -$56.8 million in 2024, then increased by 1.0% to -$56.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$56.3 million in Q4 2025, -$17.3 million in Q3 2025, and $5.6 million in Q2 2025.